IL23A and inflammatory bowel disease: These findings contribute to a deeper understanding of IBD pathogenesis and may offer insights into the effectiveness of anti-IL-12p40/IL-23 therapies and the lack of success with anti-IL-17A treatments, despite the enrichment of Th17 cells [57].